Mesoblast (ASX:MSB) Margin of Safety % (DCF FCF Based) : N/A (As of Mar. 14, 2025)

View and export this data going back to 2004. Start your Free Trial

What is Mesoblast Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Mesoblast's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Mesoblast's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Mesoblast's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Mesoblast's Margin of Safety % (DCF FCF Based) falls into.

Mesoblast Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Mesoblast's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (ASX:MSB) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

MEOBF:USA MESO:USA LWB:Germany

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.